Walgreens Boots Alliance, Inc.’s Stock Price Soars to $9.06, Marking a Positive Change of +3.78%

Walgreens Boots Alliance, Inc. (WBA)

9.06 USD +0.33 (+3.78%) Volume: 13.77M

Walgreens Boots Alliance, Inc.’s stock price is currently trading at 9.06 USD, marking an impressive increase of 3.78% in the current trading session, with a noteworthy trading volume of 13.77M. However, the performance YTD reflects a significant drop of 65.59%, indicating a turbulent year for WBA.

Latest developments on Walgreens Boots Alliance, Inc.

Walgreens Boots Alliance, Inc. (NASDAQ:WBA) has been making headlines recently with significant movements in its stock price. With Clifford Capital Partners LLC holding $7.91 million in the company and Kiltearn Partners LLP with an $8.04 million position, investor interest is evident. However, the departure of VillageMD CEO, Tim Barry, from Walgreens’ primary care arm has raised concerns about the company’s healthcare partnerships. Despite this, Charles Schwab Investment Management Inc. remains bullish with $98.28 million in holdings, while PNC Financial Services Group Inc. acquired 64,586 shares. Connor Clark & Lunn Investment Management Ltd. also took a $3.45 million position in Walgreens Boots Alliance, Inc., indicating continued investor confidence amidst recent leadership changes.

Walgreens Boots Alliance, Inc. on Smartkarma

Analysts at Baptista Research on Smartkarma have been closely monitoring Walgreens Boots Alliance Inc.’s performance and strategic shifts. In their report titled “Walgreens Boots Alliance Inc.: Capital Discipline & Store Optimization To Orchestrate A Turnaround? – Major Drivers,” they highlighted the company’s Fourth Quarter FY 2024 results and the efforts towards cost cutting, CapEx reduction, and improved working capital. The report aims to evaluate the factors influencing the company’s stock price and provides an independent valuation using a Discounted Cash Flow (DCF) methodology.

In another report by Baptista Research, titled “Walgreens Boots Alliance: Enhancing Digital & Operational Efficiency To Expand Margins! – Major Drivers,” analysts discussed the company’s performance in the third quarter of Fiscal Year 2024. The report acknowledges both positive developments and drawbacks in various areas of Walgreens Boots Alliance‘s businesses. The focus is on enhancing digital and operational efficiency to drive margin expansion and navigate through the challenges faced by the company.

A look at Walgreens Boots Alliance, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Walgreens Boots Alliance, Inc., the retail drugstore operator, has received high scores in Value and Dividend factors according to Smartkarma Smart Scores. This indicates a positive long-term outlook for the company in terms of its financial performance and ability to provide returns to its investors. However, the Growth and Resilience scores are lower, suggesting potential challenges in these areas. With a moderate Momentum score, the company may need to focus on improving its growth prospects and resilience to external factors to maintain its overall performance.

Walgreens Boots Alliance, Inc., known for its wide range of prescription and non-prescription drugs, as well as health services, faces a mixed outlook based on the Smartkarma Smart Scores. While the company excels in terms of value and dividend offerings, its growth and resilience factors are rated lower. This suggests that while investors may benefit from the company’s financial stability and dividend payments, there may be challenges ahead in terms of growth opportunities and ability to withstand market pressures. With a moderate momentum score, Walgreens Boots Alliance may need to strategize to improve its long-term performance in the changing market landscape.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma